Analysis
How can you check an Ozempic seller against counterfeit alerts?
Use FDA's dated Ozempic alerts, verify the dispensing pharmacy and escalate product concerns without treating a photograph or lot number as proof of authenticity.
Claims are checked against the sources cited in this article. Nothing here is individualized medical advice. How we research
On this page
Check FDA’s current counterfeit Ozempic alert, verify the actual dispensing pharmacy through its state licensing board, and refer product concerns to the pharmacist or manufacturer. Neither a licensed seller nor a familiar-looking pen proves a particular package is authentic; FDA’s alert describes counterfeit products using a lot number that also belongs to genuine product. FDA Ozempic alert.
Sources checked October 9, 2026. This guide explains how to use official alerts and verification channels, not how to certify a medicine at home from photographs. The date and exact identifiers matter because FDA’s page contains multiple investigations, not one permanent rule covering every product.
Start with the official alert, not a reposted image
The FDA page’s December 5, 2025 update reports seized counterfeit Ozempic injection 1 mg labeled with lot PAR1229. FDA explicitly says that number is also authentic. Its notice explains a label-placement difference in the counterfeit products it investigated and includes the corresponding photograph.
That detail should not be reduced to “all PAR1229 is counterfeit.” The same notice distinguishes authentic product supplied through Novo Nordisk’s Patient Assistance Program. Nor should another lot number be treated as proof that a package is genuine: the alert identifies known cases, not a certification database for every possible package.
Read the FDA notice directly before acting on a social-media comparison. Reposts can remove the investigation date, product form or qualification that gives an identifier its meaning. A screenshot may help locate an official notice, but the notice itself is the source to use with the pharmacist.
Keep earlier investigations separate
The same page also contains an April 14, 2025 update referring to lot PAR0362 together with serial numbers beginning 51746517. Its December 21, 2023 section refers to lot NAR0074 and serial 430834149057. These are separate dated identifiers, not alternative spellings of the December 2025 investigation.
| FDA notice date | Identifier context in the notice |
|---|---|
| December 5, 2025 | PAR1229 also belongs to authentic product; notice adds specific label-placement information |
| April 14, 2025 | PAR0362 with serial-number prefix 51746517 |
| December 21, 2023 | NAR0074 with serial 430834149057 |
The identifiers above are a navigation aid to the official alert, not a complete counterfeit-detection test. Preserve the full product details when asking a pharmacist about a concern. Do not combine a lot from one update with a serial from another and call that an FDA finding.
Verify the pharmacy that actually dispenses the prescription
FDA advises obtaining Ozempic with a valid prescription through a state-licensed pharmacy. Its online-pharmacy licensing resource links to state boards so readers can check the actual named dispenser.
A telehealth company, marketplace or advertising website may arrange care without being the pharmacy. Ask which pharmacy fills the order and match its name and address against the licensing record. If a label names a pharmacy, do not assume the business prepared or supplied the product without confirmation when there is a concern.
FDA’s unapproved GLP-1 statement also describes fraudulent compounded labels naming pharmacies that did not prepare the products. That is a separate product-category issue, but it reinforces the need to confirm the actual dispenser rather than trust a name printed on a package.
Licensing is a credential, not package authentication
FDA’s Ozempic alert reports counterfeit units reaching the legitimate U.S. drug supply chain. A licensed pharmacy check is important, but it cannot independently establish the contents and provenance of every package.
Similarly, a manufacturer’s name, familiar carton, professional website or positive reviews do not complete an authenticity check. Those clues can be copied or can describe the seller rather than the particular shipment. The right response to a material concern is investigation through the dispensing pharmacy and official manufacturer/regulator channels, not an assumption that a recognizable appearance resolves it.
Our company directory and semaglutide guide describe provider services and links. Inclusion in a directory is not a guarantee that a particular medicine is genuine, FDA-approved or suitable for an individual.
Distinguish compounded products from purported branded Ozempic
FDA defines counterfeit medicines as products represented as authentic when they are not. A product openly described as compounded belongs to a different regulatory category from the branded Ozempic package addressed in the alert. FDA’s compounding FAQ explains that compounded finished medicines are not FDA-approved.
That distinction does not provide a blanket clearance for compounds or their advertising. It prevents a different mistake: treating a compounded-product price comparison as proof of branded Ozempic authenticity, or treating every unbranded semaglutide listing as the specific counterfeit package in an FDA alert.
Identify what the seller claims to supply. If it says branded Ozempic, investigate that finished product and its dispensing chain. If it says compounded semaglutide, the pharmacy, formulation and applicable regulatory questions remain separate. Do not let a vague ingredient-only description substitute for a clear product identity.
What to do with a concern
Keep the package information, pharmacy details and transaction record available for the pharmacist’s investigation. FDA’s alert provides Novo Nordisk customer care at 1-800-727-6500 for authenticity questions and links to product-problem and MedWatch reporting channels. Follow the current notice for the relevant contact information and directions.
Report the concern through official channels rather than sending prescription identifiers or private health information to an unfamiliar verification website. FDA’s counterfeit-medicine page explains its broader investigation and reporting resources. A report is information for investigation, not an immediate determination of what a package contains.
The useful approach combines three checks: the dated official alert, the actual dispensing pharmacy and an appropriate escalation channel. Known lot and serial identifiers help direct a question, but they do not turn a photograph-based inspection into proof of authenticity. Keep that limit clear when comparing sellers or deciding whom to contact about a suspicious product.